NCT01297062 - A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2011

Conditions

Healthy Subjects

Interventions

DRUG

Exenatide

IV Exenatide (therapeutic and supratherapeutic concentrations)

DRUG

Moxifloxacin

Oral Moxifloxacin (400 mg)

DRUG

Placebo comparator

IV Placebo (matching volume of placebo)

Trial Locations (2)

Research Site, Daytona Beach

Research Site, Evansville